Current Report Filing (8-k)
05 December 2020 - 4:31AM
Edgar (US Regulatory)
0001621443
false
0001621443
2020-12-04
2020-12-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15 (d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 4, 2020
ZYNERBA PHARMACEUTICALS, INC.
(Exact Name of Issuer as Specified in Charter)
Delaware
|
|
001-37526
|
|
26-0389433
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
80 W. Lancaster Avenue, Suite 300
Devon, PA 19333
(Address of Principal Executive Offices)
(484) 581-7505
(Registrant’s Telephone Number, Including
Area Code)
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
Securities registered pursuant to Section
12(b) of the Act:
Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
|
¨
|
Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
|
¨
|
Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
ZYNE
|
|
The NASDAQ Global Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.
On December 4, 2020, Zynerba Pharmaceuticals,
Inc. issued a press release announcing that it is presenting two posters describing efficacy, safety and quality of life results
of the Phase 2 BELIEVE (Open Label Study to Assess the Safety and Efficacy of Zygel™ (ZYN002) Administered
as a Transdermal Gel to Children and Adolescents with Developmental and Epileptic Encephalopathy)
clinical trial at the 2020 virtual annual meeting of the American Epilepsy Society.
A copy of the press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference.
|
Item 9.01
|
Financial Statements and Exhibits
|
The following exhibits are being filed herewith:
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 4, 2020
|
ZYNERBA PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Suzanne Hanlon
|
|
|
Name: Suzanne Hanlon
|
|
|
Title: Secretary, Vice President and General Counsel
|
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Apr 2024 to May 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From May 2023 to May 2024